← All trials
NCT04636671
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2020
- Primary completion
- Mar 31, 2021
- Completion date
- Apr 30, 2021
- First posted
- Nov 19, 2020
- Last posted
- Nov 19, 2020
- Enrollment
- 680
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TriesteLead sponsor
- Centro di Riferimento Oncologico - AvianoCollaborator
- University of TriesteReponsible party - principal investigator
- University of TriesteOverall official - principal investigator
- Istituto Nazionale Malattie Infettive Lazaro SpallanzaniCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.